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Characterization of Postinfusion Phenotypic Differences
in Fresh Versus Cryopreserved TCR Engineered
Adoptive Cell Therapy Products
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Summary: Adoptive cell therapy (ACT) consisting of genetically
engineered T cells expressing tumor antigen-speciﬁc T-cell receptors
displays robust initial antitumor activity, followed by loss of T-cell
activity/persistence and frequent disease relapse. We characterized
baseline and longitudinal T-cell phenotype variations resulting from
different manufacturing and administration protocols in patients
who received ACT. Patients with melanoma who enrolled in the
F5-MART-1 clinical trial (NCT00910650) received infusions of
MART-1 T-cell receptors transgenic T cells with MART-1 peptide-
pulsed dendritic cell vaccination. Patients were divided into cohorts
based on several manufacturing changes in the generation and
administration of the transgenic T cells: decreasing ex vivo stim-
ulation/expansion time, increased cell dose, and receiving fresh
instead of cryopreserved cells. T-cell phenotypes were analyzed by
ﬂow cytometry at baseline and longitudinally in peripheral blood.
Transgenic T cells with shorter ex vivo culture/expansion periods
displayed signiﬁcantly increased expression of markers associated
with less differentiated naive/memory populations, as well as
signiﬁcantly decreased expression of the inhibitory receptor
programmed death 1 (PD1). Patients receiving fresh infusions of
transgenic cells demonstrated expansion of central memory T cells
and delayed acquisition of PD1 expression compared with patients
who received cryopreserved products. Freshly infused transgenic
T cells showed persistence and expansion of naive and memory
T-cell populations and delayed acquisition of PD1 expression,
which correlated with this cohort’s superior persistence of transgenic
cells and response to dendritic cell vaccines. These results may be
useful in designing future ACT protocols.
Key Words: melanoma, adoptive cell therapy, T-cell phenotype,
memory T cells, PD1
(J Immunother 2018;41:248–259)
Immunotherapy can be an effective means of treating orcuring a variety of advanced malignancies. These
approaches generally rely on CD8+ cytotoxic T lymphocytes
(CTL), which recognize tumor antigens via their T-cell
receptor (TCR), and then induce tumor cell death via
effector molecules such as granzyme B, engaging tumor
necrosis factor family of death receptors, and interferons.
Adoptive cell therapy (ACT) involves the ex vivo generation
of CD8+ T cells which target speciﬁc tumor antigens.1 These
T cells can be generated ex vivo by expansion of tumor-
inﬁltrating lymphocytes (TILs) from a given tumor,2
expansion of endogenous, low-frequency CD8+ T cells
which target a tumor antigen,3,4 or, most recently, by
genetic transfer of a TCR with speciﬁcity to a given tumor
antigen.5 Such products are then expanded ex vivo and
reinfused into the patient. Several groups have previously
demonstrated that ACT typically results in frequent initial
tumor responses, but with infrequent long-term responses.
Prior landmark ACT clinical trials by Rosenberg and col-
leagues at the National Cancer Institute, Surgery Branch
demonstrated complete responses in a minority of patients
treated with genetically engineered T cells directed against
melanoma-speciﬁc antigens MART-1 and gp100.6,7 Addi-
tional antigens and their associated malignancies have been
targeted in this manner as well, most notably with anti-NY-
ESO-1 TCR-engineered T cells used to treat NY-
ESO-1+ melanomas and synovial sarcomas.8,9 However,
despite robust initial tumor responses in the majority of
patients treated in these trials, complete responses without
recurrence were only seen in a minority of patients. This
widely reproduced phenomenon underscores the need to
better understand the behavior of the genetically modiﬁed
T cells utilized in ACT to enhance the duration of their
initially strong antitumor effects.
Our group’s prior experience with ACT, the University of
California, Los Angeles/CalTech F5-MART-1 clinical trial,
utilized autologous T cells which had undergone retroviral
transduction to express a TCR against MART-1 and
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subsequently expanded ex vivo, in conjunction with autologous
MART-1 peptide-pulsed dendritic cells (DCs) to treat patients
with locally advanced or metastatic melanoma.10 Nine of the 13
treated patients (69%) showed evidence of transient tumor
regression by computed tomography or positron emission
tomography/computer tomography. Peripheral blood recon-
stitution withMART-1-speciﬁc T cells peaked within 2 weeks of
ACT, indicating dramatic in vivo expansion. However, none of
the initial tumor responses were durable beyond 6 months. We
had previously analyzed TCR transgenic T cells administered
and recovered from 3 of the patients in this series using new
generation microﬂuidics-based miniaturized assays. These
assays allow us to simultaneously study multiple functional
cytokine responses of T cells based on deﬁned antigen
speciﬁcities.11,12 These studies showed that the initial poly-
functionality and cytotoxicity resulting in high antitumor
activity of the TCR transgenic T cells is gradually lost in vivo,
which was temporally associated with the clinical course of
initial tumor response followed by progression.
The need for improving ACT’s efﬁcacy has led to the
characterization of factors responsible for the success or
failure of these therapies. Prior work by Restifo and col-
leagues has demonstrated the role of less differentiated T
cells in successful ACT, primarily the naive T cell (TN) and
central memory T cell (TCM) compartments. Mouse models
have revealed that ACT with these less differentiated T-cell
subsets demonstrate superior in vivo expansion, persistence,
and antitumor activity when compared with the more
terminally differentiated effector memory (TEM) and effec-
tor (TEFF) T-cell compartments.13,14 Furthermore, they
have shown that TEFF cells derived from naive T cells resist
terminal differentiation and have greater proliferative
potential than TEFF derived from memory T-cell
populations.15,16 In addition, the loss of antitumor activity
in mouse models of ACT has been associated with the
acquisition of inhibitory receptors such as programmed
death 1 (PD1) on both tumor-inﬁltrating lymphocytes
(TILs) and circulating CTLs, and the addition of agents
blocking these inhibitory receptors potentiates the activity of
ACT in these preclinical models.17
Our F5-MART-1 trial utilized several manufacturing
changes in the generation and administration of the modi-
ﬁed T cells, namely decreasing ex vivo stimulation/expan-
sion time from 7 to 6 days, increasing the number of cells
infused, and the use of fresh instead of cryopreserved
cells. Of note, our patients who received fresh TCR trans-
genic T cells were noted to experience a more prolonged
persistence of circulating transgenic T cells, as well as
reexpansion of the transgenic cells in response to the
MART-1 peptide DC vaccinations.10 We therefore chose to
longitudinally study the transgenic T cells in our patients
to understand the phenotypic effect of the differences
in manufacturing techniques employed. We report that
shorter ex vivo culture/expansion periods are associated
with increases in expression of T-cell markers of naive/
memory phenotypes, and that this phenotype persists longer
in freshly infused cells compared with cryopreserved cells.
In addition, while shorter culture time was associated
with decreased initial expression of the inhibitory TCR
programmed death 1 (PD1), freshly infused cells demon-
strated delayed acquisition of PD1 when compared with the
cryopreserved cells. These differences may be responsible
for these patients displaying increased persistence of their
transgenic T-cell products, as well as their responsiveness
to DC vaccinations. These ﬁndings may help inform the
optimization of future ACT protocols, and lead to improved
treatment outcomes.
METHODS
Clinical Trial, Patients, and Manufacturing
Cohorts of MART-1 Engineered T Cells
Patients positive for HLA-A*0201 and with a MART-1+
metastatic melanoma were enrolled in the F5-MART-1 clinical
trial (NCT00910650) from April 2009 to September 2011.
A written consent form for the University of California Los
Angeles (UCLA) Institutional Review Board (#08-02-020 and
#10-001212) was obtained from each patient, under investiga-
tional new drug 13859 from the US Food and Drug
Administration.10,12 Detailed descriptions of the clinical trial
design and manufacturing of the MART-1 TCR transgenic
T cells are previously described.10 We divided the patients into
4 cohorts for immune monitoring analyses following sequential
amendments to the TCR transgenic T-cell manufacturing.
Brieﬂy, cohort 1 (patients F5-1 through F5-4) was treated
under the original protocol, in which nonmobilized peripheral
blood mononuclear cells (PBMCs) were stimulated in culture
with IL-2/OKT3 and were transduced with our clinical grade
retrovirus vector expressing the MART-1 F5 TCR on 2 con-
secutive days, and were then continually expanded for 96 hours
(7 d total culture time), after which they were cryopreserved as
soon as the lot release criteria were cleared, and subsequently
receiving up to 1×109 previously cryopreserved TCR transgenic
lymphocytes. Cells were infused into patients following a con-
ditioning regimen with cyclophosphamide and ﬂudarabine,
along with up to 14 doses of IL-2, as previously described.10
Cohort 2 (patients F5-5 through F5-9) limited the period of
ex vivo expansion to 72 hours following transduction (6 d total
culture time) before cryopreservation and subsequent admin-
istration of 1×109 TCR transgenic lymphocytes. Cohort 3
(patients F5-10 and F5-11) increased the total number of cry-
opreserved TCR transgenic lymphocytes given to up to a
maximum of 1×1010, while total culture time remained 6 days
total. Cohort 4 (patients F5-12 through F5-14) received fresh
infusions of up to 1×1010 TCR transgenic lymphocytes, rather
than cryopreserved. In addition, these patients received 1 day
less of ﬂudarabine conditioning, and were given only a max-
imum of 9 doses of IL-2 instead of 14. Culture time remained
6 days total for this cohort. Patient F5-15 also received freshly
infused cells, but with a maximum of only 1×109 cells. This
patient also received more frequent administration of IL-2, but
at lower dosage.
Flow Cytometry Surface Staining
PBMCs were centrifuged (400g for 5min), resuspended in
100 μL of adult bovine serum (Omega Scientiﬁc, Tarzana, CA)
and stained with preconjugated antibodies for ﬂow cytometry,18
and acquired using 2 LSR II Flow Cytometers, one with 3 lasers
(blue, red, and violet) and the other with 4 lasers (blue, red,
violet, and ultraviolet; BD Biosciences, San Jose, CA). A mini-
mum of 500,000 events were captured for each experiment.
Antibodies against CD3, CD8, CD4, CD25, HLA-DR,
CD45RO, CCR7, CCR5, PD1, CD45RA, CD27, CD28 and
CD62L, as well as 7-Aminoactinomycin D, were purchased
from BD Biosciences, Beckman Coulter (Brea, CA), Biolegend
(San Diego, CA), and Thermo Fisher Scientiﬁc (Waltham,MA).
MART-1 HLA-A*0201 Tetramers and negative controls were
purchased from Beckman Coulter. Detailed description of the
antibodies and staining is described in previously published
articles.10,12 For CD8+ T-cell phenotype characterization, TN
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were classiﬁed as CD45RA+/CCR7+/CCR5−/PD1−, CD45RA+/
CCR7+/CCR5−/PD1+, CD45RA+/CCR7+/CCR5+/PD1−, and
CD27+/CD28+/CD62L+; TCM as CD45RO+/CD25−/HLA-
DR−/CD127+, CD45RA−/CCR7+/CCR5−/PD1−, and CD27+/
CD28−/CD62L+; TEM as CD45RA−/CCR7−/CCR5−/PD1−,
CD45RA−/CCR7−/CCR5−/PD1+, CD45RA−/CCR7−/CCR5+/
PD1−, and CD45RA−/CCR7−/CCR5+/PD1+; effector memory
RA (TEMRA) as CD45RA+/CCR7−/CCR5+/PD1−, CD45RA+/
CCR7−/CCR5+/PD1−, CD45RA+/CCR7−/CCR5+/PD1−,
CD45RA+/CCR7−/CCR5+/PD1−; and TEFF as CD45RO+/
CD25+/HLA-DR+/CD127−, CD45RO+/CD25+/HLA-DR−/
CD127−, and CD45RO+/CD25-/HLA-DR−/CD127−. For
CD4 phenotype characterization, suppressor T regulatory
cells (Treg) were deﬁned as CD4+/CD25+/CD127−.
Flow Cytometry Analysis
All ﬂow data analyses were done with either FlowJo
(Tree Star Inc., Asland, OR) or Cytobank (www.cytobank.
com).19 Biexponential and arcsinh displays were used in the
analyses.
Statistical Analysis
Graphing, heatmaps, and descriptive statistical analy-
ses were carried out with GraphPad Prism version 7.0
(GraphPad, San Diego, CA). For the comparison of the
characteristics of the 7 day versus 6 day culture cohorts’
infusion products, unpaired Student t test was used. Log-
transformation was performed if normality assumption was
violated according to the Shapiro-Wilk test. P-values of
<0.05 were considered statistically signiﬁcant.
RESULTS
Patient Characteristics and Outcomes
As previously described,10 there were multiple protocol
amendments during this trial, which signiﬁcantly altered
the manufacturing of the infused cell products as described
previously. The 4 manufacturing cohorts and their asso-
ciated differences are summarized and subdivided on
Table 1, along with patient characteristics and outcomes.
There was transient evidence of initial tumor response to
ACT in 9 of 13 patients as determined by day 30 computed
tomography or positron emission tomography/computer
tomography scans. In patients who survived to the end of
the study, 8 demonstrated stable disease, while 4 showed
progressive disease. One subject, F5-5, was ultimately
ineligible for the trial due to the discovery of brain meta-
stases shortly after the subject was enrolled, and did not
receive his transgenic T-cell infusion product. Another
subject, F5-15, was enrolled after an additional amendment
to our protocol changing the IL-2 administration from high
dose intravenously to low dose subcutaneously bid for up to
14 days, therefore this patient received more frequent dosing
of IL-2, but at lower dosing. Patient F5-15 also had reduced
number of infused cells (the original 1×109 cells used in the
earlier cohorts). All patients ultimately died of their under-
lying metastatic melanoma. Progression-free survival ranged
from 0 to 7 months, while overall survival ranged from 1 to
86 months (Table 1).
Patient F5-10 suffered bone marrow failure secondary
to disease progression, and we were unable to obtain any
longitudinal samples beyond the ﬁrst 15 days. We were also
unable to obtain any samples between day +30 and day
+100 in patient F5-11 due to signiﬁcant adverse events
(SAEs) during this period. Patients F5-12 and F5-13
experienced SAEs related to IL-2 administration, and sam-
ples before day +15 were unable to be obtained. We were
also unable to obtain samples longitudinally for patients F5-
14 and F5-15 due to SAEs within the ﬁrst month, and they
passed away in the ﬁrst month following T cell infusion.
Baseline Phenotypic Differences Between
Manufacturing Cohorts of MART-1 Transgenic
T Cells
We ﬁrst examined the phenotypic differences between
cohort 1 and cohorts 2, 3, and 4 to explore the effects of
shorter ex vivo culture and expansion time (7 vs. 6 days).
We found no signiﬁcant differences in the CD4+/CD8+
ratio between 7-day and 6-day culture/expansion times
(1.78 vs. 2.70, Fig. 1B). Eleven surface markers were used
to phenotypically classify the MART-1 transgenic T-cell
products as described previously. The transgenic CD4+
T-cell subset (Fig. 1D) demonstrated signiﬁcantly higher
CCR7 expression in the 6-day culture time cohorts than in
the 7-day culture cohort (25.3% vs. 1.38%, P< 0.05), as
well as higher expression of CD62L (66.2% vs. 30.3%,
P< 0.05). In addition, there was increased CD25 expres-
sion noted in the 6-day culture time cohorts compared
with the 7-day culture cohort (84.0% vs. 43.3%, P< 0.01).
In the transgenic CD8+ subset (Fig. 1E), CCR7 elevation
in shorter culture time nearly achieved signiﬁcance (23.1%
vs. 1.4%, P= 0.066). However, CD62L expression was
signiﬁcantly higher in the shorter culture time cohorts
compared with cohort 1 (70.4% vs. 34.0%, P< 0.01).
Furthermore, the inhibitory receptor PD1 displayed sig-
niﬁcantly lower expression in the cell products which had
been cultured for 6 days compared with 7 days (7.0% vs.
27.3%, P< 0.05).
Persistence of Naive/Memory T Cells in Freshly
Infused Transgenic Product
We compared the changes in transgenic T-cell pheno-
type between the different manufacturing/administration
protocols over time for patients in whom we were able to
obtain longitudinal PBMC samples (patients F5-1 through
F5-4 in cohort 1, patients F5-6 through F5-9 in cohort 2,
patients F510 and F5-11 in cohort 3, and patients F5-12 and
F5-13 in cohort 4). The most striking trends in both the
CD4+ and CD8+ populations displayed were a persistence
of the naive/memory T-cell markers CD127 and CCR7 in
cohorts 2, 3, and 4, as well as a signiﬁcant delay in the
acquisition of PD1 in cohort 4 (Fig. 2). While there was
negligible expression of CD127 at baseline and longitudi-
nally in the CD8 transgenic cells in cohort 1 (< 1% positive
average, Fig. 2A), this memory T-cell marker expanded
beyond its baselines in cohort 2 (from 5.99% to 47% at end
of study), cohort 3 (from 7.5% to 21.3%) and cohort 4 (from
5.4% to 70.5%). The marker of memory/naivety CCR7
remained at <1% of transgenic CD8+ T cells for cohort 1.
Despite starting off at higher levels in cohorts 2 and 3
(27.7% and 36.7%, respectively), CCR7 average expression
levels gradually diminished over time in these cohorts.
Cohort 4, however, displayed a longitudinal expansion of
CCR7, reaching a peak of 62.1% average positivity at day
+45, and a persistence of this expression up to day +100
(31%). When transgenic CD8+ T cells were stratiﬁed by
naive/central memory/effector memory/effector memory
RA/effector phenotypes (Fig. 2B), we observed a con-
traction of TN and TCM compartments in cohort 1 (from
8.2% and 6.5% to 4.2% and 2.6% of total, respectively),
Nowicki et al J Immunother  Volume 41, Number 5, June 2018
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TABLE 1. Patient Demographics, Outcomes, and Distribution by Manufacturing Cohort
Manufacturing/
Conditioning Cohort
Patient
Study No.
Sex
(M/F)
Age
(y)
Active Metastasis
Sites Stage
No. F5 TCR
Transgenic Cells
No. Doses
IL-2
No. Doses
DCs
Evidence of Transient
Tumor Response
Response at
EOS (Day 90)
PFS
(mo)
OS
(mo)
1 (7 d expansion,
cryopreserved,
up to 1×109 cells infused)
F5-1 M 60 Lung, stomach, liver,
pancreas,
peritoneum, soft
tissues
M1c 1×109 12/14 3/3 Yes by PET/CT Progression 3 5
1 F5-2 F 46 Skin, LN, bone M1c 1×109 6/14 3/3 Yes by PET/CT Stable disease 6 10
1 F5-3 M 61 Lung, liver M1c 1×109 13/14 3/3 Yes by PET/CT Stable disease 7 86
1 F5-4 M 50 Lung, LN, SC M1c 0.6×109 14/14 3/3 No Progression 2 22
2 (6 d expansion,
cryopreserved,
up to 1×109 cells infused)
F5-5 M 53 Lung M1c NA NA NA NA NA NA NA
2 F5-6 M 59 Lung, LN M1b 1×109 13/14 3/3 Yes by PE Stable disease 3 4
2 F5-7 M 48 SC, bone M1c 1×109 9/14 3/3 Yes by CT Stable disease 4 11
2 F5-8 M 44 LN, liver M1c 1×109 11/14 3/3 Yes by PET/CT Stable disease 4 11
2 F5-9 F 46 Skin, LN M1a 1×109 11/14 3/3 No Progression 3 20
3 (6 d expansion,
cryopreserved,
up to 1×1010 cells infused)
F5-10 F 47 Liver, adrenal, SC,
LN, orbit
M1c 4.8×109 14/14 2/3 Yes by PET/CT Progression 2 8
3 F5-11 F 56 Lung, LN M1b 1.8×109 8/14 3/3 Yes by PET/CT Stable disease 4 10
4 (6 d expansion, fresh, up to
1×1010 cells infused, reduced
conditioning and IL-2)
F5-12 M 40 Lung, LN MIVb 3.9×109 6/9 3/3 Yes by PET/CT Stable disease 5 8
4 F5-13 M 60 Lung, abdomen, SC MIIIb 4.41×109 4/9 3/3 Yes by PET/CT Stable disease 3 8
4 F5-14 F 50 Lung, liver, adrenal
gland, LNs
M1c 3.93×109 3/9 1/3 Yes by CXR NA (died 31 d
following
T-cell infusion)
0.5 1
4 (6 d expansion, fresh, up to
1×109 cells infused, reduced
conditioning and low dose
IL-2)
F5-15 M 76 Right axilla, chest
wall, lungs, liver
MIV 1×109 22/28 1/3 NA NA (died 12 d
following
T-cell infusion)
NA NA
CXR indicates chest x-ray; DC, dendritic cells; EOS, end of study; F, female; IL, interleukin; LN, lymph nodes; M, male; NA, not available; OS, overall survival; PE, physical examination; PET/CT, positron emission
tomography/computer tomography; PFS, progression-free survival; SC, subcutaneous; TCR, T-cell receptor.
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compared with a starting higher average proportion TN and
TCM subpopulations of T cells within cohort 2 (TN 23.3%,
TCM 5.9%) and cohort 3 (TN 18.1%, TCM 3.8%), as well as
overall persistence of these compartments by the end of
study (cohort 2—TN 17.7%, TCM 5.9%; cohort 3—TN
19.6%, TCM 8.7%). Furthermore, while cohort 4 displayed a
higher average amount of TN (15.0%), which contracted to
5.5% of total by the end of the study, there was an overall
expansion of TCM cells in this cohort (from 3% to 34.9%) by
day +100.
Several trends were also apparent within the CD4+
population of transgenic T cells (Fig. 2C): CD127 expres-
sion was negligible in cohort 1, achieving a maximum
expression of 15.8% on day +75, which was not sustained.
Conversely, cohort 2 achieved continual expansion of
CD127 to a maximum of 76.1% by day +90, while cohort 4
achieved a rapid expansion of CD127 to an average of
97.3% positive, with persistence of 67.5% positive by day
+100 (there were no detectable CD4+ transgenic T cells after
day +30 in cohort 3). CCR7 also remained negligible in
cohort 1 throughout the study. Cohort 2 displayed a late
expansion of this memory marker to 49.3% at day +80,
while cohort 4 displayed an expansion of this marker to
64.8% at day +30, with a persistence of 32.4% positive by
day +100.
Delayed PD1 Acquisition in Freshly Infused
Transgenic Product Compared With
Cryopreserved Product
The T cell inhibitory marker PD1 also displayed dif-
ferent longitudinal dynamics in cohort 4, which received
fresh infusions of transgenic cells, as compared with the
cryopreserved cohorts. Although cohorts 2, 3, and 4 all
displayed signiﬁcantly lower PD1 expression than cohort 1
at baseline, cohorts 2 and 3 displayed progressive acquis-
ition of PD1 within a week of infusion. Cohort 1, which
displayed an average PD1 expression of 27.3% and 18.2% in
the transgenic CD8+ and CD4+ compartments, respectively,
increased steadily to peaks of 57.7% and 84% within the
transgenic CD8+ and CD4+ compartments, respectively
(Figs. 2A, C). Cohorts 2 and 3, which initially had only
7.3% and 7.8% average PD1 expression in the CD8+
FIGURE 1. Immune phenotypic analysis of MART-1 transgenic T cells in the final product. A, Gating strategy used to extract the
percentage of transgenic CD4 and CD8 T cells. B, Ratio of CD4 versus CD8 cells. C, Gating strategy to extract the immune markers. D and
E, Comparison of immune marker expression in MART1+ CD4+ (D) and CD8+ (E) T cells, comparing the 7-day culture/expansion cohort—
cohort 1 (n=4), to the 6-day culture/expansion cohorts—cohorts 2, 3, and 4 (n=11). Dots represent individual data points, lines
indicate means. *P<0.05; **P<0.01.
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transgenic cells at infusion, displayed a rapid and steady
increase in the acquisition of this marker within the ﬁrst
week, rising to maximums of 75.6% and 27.5%, respectively.
This trend was mirrored within the CD4+ transgenic T-cell
population as well, with rapid rises from baselines of 12.0%
and 9.2% to maximums of 56.4% and 25.0% within cohorts
2 and 3, respectively. Cohort 4 displayed low PD1 expres-
sion at baseline within the CD8+ and CD4+ transgenic
populations (1.0% and 2.0%, respectively). However, PD1
expression remained nearly undetectable (< 1%) in both the
CD4+ and CD8+ transgenic cell population in this cohort
until day +55, reaching maximums of only 28.4% and
28.7%, respectively.
We also examined the total proportion of CD8+PD1+
circulating lymphocytes in our patients, to examine the
overall trends of this population, as well as proportion of
transgenic CD8+PD1+ cells which made up the total of this
phenotype (Fig. 3). Overall, the proportion of transgenic
CD8+PD1+ T cells which made up the total quantity of
CD8+PD1+ T cells remained the same or was slightly aug-
mented within the ﬁrst 30 to 45 days postinfusion, after
which it remained roughly proportional in cohort 2, while
modestly contracting in cohorts 1 and 3. Cohort 4, by
comparison, maintained the lowest overall population of
CD8+PD1+ T cells, only minimally expanding both the total
and transgenic populations after day +55.
Presence of Suppressor Tregs Within Infusion
Products, Followed by Rapid Clearance
In order to understand the progressive loss of trans-
genic cell number and activity over time, we explored the
presence of suppressor Tregs within the infusion product and
over time (Fig. 4). Signiﬁcant proportions of both transgenic
and nontransgenic T cells with a Treg phenotype were
present within the infusion product in all cohorts, with no
signiﬁcant differences between manufacturing cohorts.
However, all transgenic Tregs were cleared from circulation
within the ﬁrst 15 days. This was accompanied by an overall
decrease in total Tregs as well. Cohort 4 did not have sufﬁ-
cient samples collected for day +15 analysis of Tregs, but all
total and transgenic Tregs were cleared from this cohort by
day +30.
FIGURE 2. Longitudinal changes in phenotypic markers on MART-1 transgenic T cells. A and C, Heatmap representing changes in
average percentages of transgenic CD8 T cells (A) and CD4 T cells (C) between the 4 manufacturing cohorts over time. Average percent
positivity of a given marker is expressed in color scale from white (0%) to blue (100%), color scales are expressed to the right. Figures
represent pooled data within each cohort. B, Phenotypic changes of CD8+MART-1+ T cells. The average percentage of each T-cell
phenotype (naive, central memory, effector memory, effector memory RA, and effector) is represented by a different color. Gating
strategies are the same as in Figure 1C. Error bars represent SEM. Cohort 1: n=4, cohort 2: n=4, cohort 3: n=2, cohort 4: n=2.
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MART-1 Transgenic CD8 T Cells Track to Tumors,
and these TILs Acquire Expression of PD1
We next characterized the ability of transgenic T cells
to track to the tumor sites, as well as their phenotypic
changes within the tumor microenvironment, by examining
on-treatment tumor biopsies in the 2 patients from whom we
were able to obtain such biopsies (F5-1 and F5-2) at day
+24 and day +30, respectively. We then compared the
infusion T cells, day +30 peripheral blood CD8+ T cells, and
tumor biopsy TILs (Fig. 5). Patient F5-1, who displayed
82.3% expression of MART-1 tetramer in the infusion
product, displayed persistence of 38.8% in peripheral blood
CTLs at day +30, while TILs isolated from the tumor
biopsy displayed 10.7% MART-1 tetramer positivity
(Fig. 5A). Patient F5-2 similarly displayed a robust
expression of MART-1 tetramer in the infusion product
(63.1%), which both persisted in the peripheral blood (43.5%
positive at day +30), and were detectable in the tumor at day
+30 as well (9.85% positive in TILs). We further charac-
terized the degree of PD1 acquisition within both the
peripheral blood transgenic CTLs and TILs. Patient F5-1,
who displayed 22.6% PD1+ CD8+MART-1+ cells in the
infusion product (Fig. 5C), showed elevated PD1 expression
within the transgenic CD8+ population within both the
peripheral blood and TIL compartments (83.4% and 64.4%,
respectively). While patient F5-2 showed a transient
decrease in overall PD1 expression in the peripheral blood
by day +30 (from 19.5% to 1.3%), the CD8+MART-1+ TILs
demonstrated increased expression of PD1 (38.2%).
In order to better characterize this acquisition of PD1
expression within the TILs of these patients, we examined PD1
acquisition within the TEM and TEMRA compartments using the
canonical Boolean gate approach.20 As before, TEM was
deﬁned as CD45RA−/CCR7−/CCR5+/−/PD1+/−, while TEMRA
was deﬁned as CD45RA+/CCR7−/CCR5+/−/PD1+/−. In patient
F5-1, PD1− transgenic CD8 T cells represented 57.2% of the
TEM compartment in the infusion product (Fig. 5D). These
PD1− cells had disappeared completely from the peripheral
blood by day +30, and remained only minimally present within
the TILs (7.6%). However, the PD1+ transgenic CD8+ T-cell
population increased from 8.1% of the TEM compartment in
the infusion product to 57.3% of this compartment within the
TILs. This trend was also seen in the TEMRA compartment as
well: PD1− transgenic TEMRA cells decreased from 19% in the
FIGURE 3. Baseline and longitudinal proportions of total and transgenic CD8+PD1+ T cells in patients. A, Gating strategy to obtain the
percentage of CD8+PD1+ T cells, and percentage of MART-1 tetramer expressing cells within that population. B, Total frequency of
PD1+CD8+ expressing T cells (white), and the proportion of those cells expressing the MART-1 TCR (red) in the final infusion product and
on circulating peripheral lymphocytes of the patients over time (measured in days). Error bars represent SDs. Cohort 1: n=4, cohort 2:
n=4, cohort 3: n=2, cohort 4: n=2.
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infusion product to 11.9% in the peripheral blood and 5.3% in
the TILs, while PD1+ transgenic TEMRA increased in both the
peripheral blood and within the TILs (81% and 25.9%,
respectively). Patient F5-2 also displayed acquisition of PD1
expression within the TEM compartment, with PD1− transgenic
TEM cells falling from 58.3% in the infusion product to 20.3%
and 5.7% in the peripheral blood and TILs at day +30,
respectively (Fig. 5D). Conversely, PD1 expression in the TEM
compartment rose from 3.9% in the infusion product to 45.7%
in the TILs (while disappearing from the peripheral blood).
Within the TEMRA compartment, patient F5-2 demonstrated
an expansion of PD1− transgenic cells in the peripheral blood,
while still showing acquisition of PD1 expression within the
transgenic TILs (from 2.1% to 8.6% of total).
DISCUSSION
Given the ability of ACT to generate robust initial
antitumor responses, there is interest in exploring ways of
enhancing its therapeutic duration. In addition, as manu-
facturing protocols of cellular products can vary between
institutions, characterization of phenotypic differences resulting
from variations in manufacturing practices is an important topic
with therapeutic implications. Previous preclinical models of
ACT have demonstrated that prolonged ex vivo expansion
resulted in transgenic T cells which were more terminally dif-
ferentiated, had decreased proliferative capacity, and lower
antitumor activity in vivo when compared with products with
shorter ex vivo expansion periods.13,21,22 Therefore, our
F5-MART-1 trial had utilized a 7-day, and later a 6-day culture
period, both of which were shorter than the previously utilized 2
to 4 week expansion periods in other ACT trials.6,7 We also
infused fresh rather than cryopreserved cells in the later patients
enrolled in the trial, in an effort to improve clinical outcomes by
avoiding the physiologic stressors of freezing/thawing. These
patients’ responses differed in that they demonstrated longer
persistence of transgenic T-cell products, and were the only
cases to display evidence of boosting effects in response to the
FIGURE 4. Baseline and longitudinal proportion of total and transgenic suppressor Tregs in patients. A, Gating strategy to obtain the
percentage of Treg cells, and percentage of MART-1 tetramer expressing cells within that population. B, Total frequency of Tregs T cells,
defined by CD4+CD25highCD127Low (white), and the proportion of those cells expressing the MART-1 TCR (blue) in the final infusion
product and on circulating peripheral lymphocytes of the patients over time (measured in days). Error bars represent SDs. Cohort 1: n=4,
cohort 2: n=4, cohort 3: n=2, cohort 4: n=2.
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DC vaccines, as previously reported.10 Two patients (F5-12 and
F5-14) who received fresh cell infusions were the only patients
noted to have severe cytokine storm syndrome, which was not
seen in any patients who received cyropreserved cells, as pre-
viously reported.10 Furthermore, another patient who received
fresh cells (F5-13) displayed recall whole body rash which
accompanied the reexpansion of TCR transgenic cells in
response to DC vaccination. These results further imply a
superior functionality of the fresh transgenic cells, although the
small sample size prevents us from drawing ﬁrm conclusions.
Given the prolonged exposure to IL-2 in our culture/
expansion protocols, we were concerned that differences in
suppressor Treg populations, as well as CD4/CD8 ratios,
would contribute to loss of antitumor functionality. Using
the conventional CD25+/CD127− surface markers23–26 to
characterize Tregs (FoxP3 was not used due to its potential
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FIGURE 5. Transgenic CD8 T cells track to the site of tumor and acquire expression of PD1. A, Percent expression of MART-1+ T cells in
infused, blood and biopsy samples from patients F1 (left) and F2 (right). Scramble peptide (negative) was used for gating purposes. B,
Flow of gating strategy for the plots in (C) and (D). Following this gating, additional phenotypic markers were examined per the gating
strategy in Figure 1C. C, Percent expression of PD1 on CD8+MART-1+ T cells in patients F5-1 and F5-2 in the infusion product, peripheral
blood, and TILs. D, Percentage of PD1− and PD1+ CD8+MART-1+ T cells with the effector memory (TEM) and effector memory RA (TEMRA)
compartments in the infusion product, peripheral blood, and tumor-infiltrating lymphocytes.
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presence on effector cells),27,28 we found that while sup-
pressor Tregs were present within all infusion products, they
were rapidly cleared from circulation. Furthermore, culture
time had no effect on the CD4/CD8 ratio in the infusion
product, implying that the ﬁnal product maintains a ratio
similar to that of healthy donors (∼2) despite several days of
culture/expansion with IL-2. However, our patients in
shorter culture time demonstrated signiﬁcantly increased
surface markers associated with less differentiated naive/
memory T-cell subtypes (CCR7, CD62L, and CD127), as
well as decreased expression of the inhibitory receptor PD1.
Shorter culture times were also associated with increased
relative amounts of naive/memory T cells, which persisted
over time. While these trends have previously been observed
in preclinical models of ACT and in chimeric antigen
receptor T cells,13,21,22,29 it is remarkable that these differ-
ences were apparent in our study of TCR-engineered clinical
ACT products despite only one day less spent in culture.
Despite evidence from our group and others that cry-
opreserved T cells still maintain transient antitumor activity
and speciﬁcity,10,12,30 all cryopreserved cohorts exhibited a
relatively rapid and steady increase of PD1 expression in
transgenic T cells. This was seen both within the peripheral
circulation as well as the tumor microenvironment, in the
cases examined. Only the patients who received freshly
infused cell products experienced signiﬁcant delays in
acquisition of PD1 expression, as well as an expansion of the
central memory compartment over time. These 2 factors are
in keeping with increased persistence of transgenic CD4 and
CD8 cells noted in this cohort. While the reduced IL-2
dosing utilized in cohort 4 may have play a role in the
delayed acquisition of PD1 and persistence/expansion of
memory/naive T cells in this cohort, it would not have
affected the baseline phenotypic differences noted. Fur-
thermore, the rapid clearance of Tregs from circulation (both
in transgene positive and negative cells) implies that the IL-2
administration differences may not have yielded a signiﬁcant
overall phenotypic effect to the T cells. However, there may
be other confounding host immunomodulatory factors which
contributed to the phenotypic differences noted in cohort 4,
due to the reduced ﬂudarabine conditioning regimen which
these patients received.
Previous studies have demonstrated the importance of TN
and TCM populations in maintaining proliferative capacity and
antitumor activity of the other T-cell populations.14–16,21
However, increased central memory T cells and delayed/
decreased PD1 expression may also explain the boosting
response to DC vaccination in the cohort receiving fresh
infused cells. DCs have been shown to maximize the response
of TCM cells to antigenic challenge.31 Therefore, a larger
reserve of TCM cells could lead to enhanced response to the
DCs themselves. Furthermore, although terminally differ-
entiated TEFF can function as suppressor cells by killing DCs
in a perforin/granzyme B-dependent manner,32,33 TCM cells
themselves have been shown to protect DCs from this TEFF-
mediated killing.34 Finally, the expression of PD1 on T cells
can inhibit their interactions with DCs themselves via PD-L1
and PD-L2 expression on the DCs, and PD1 blockade can
restore such interactions.35–39 Taken together, these ﬁndings
may collectively explain why fresh infused transgenic cells
subjected to shorter expansion times displayed superior DC
vaccine responses.
Unfortunately, all patients, including those who received
fresh transgenic cells, ultimately succumbed to progressive
disease. Given that all patient cohorts eventually developed
PD1 expression, this is a likely contributor to the eventual
decrease in T cell functionality despite any persistence of the
cells. PD1 is well known to be progressively upregulated after
TCR engagement, leading to loss of T cell functionality in
multiple malignancies.40,41 With the success of preclinical
models in enhancing transgenic T-cell cancer therapies via
addition of PD1 blockade,17,42 this may represent an attrac-
tive means of perpetuating the antitumor activity of these
therapies. When combined with other factors that further
optimize T-cell persistence and activity, such as increased
naive/memory T cells and DC vaccine boosts, these measures
may yield optimal ACT responses. Furthermore, given the
apparent advantages of fresh transgenic cells over cry-
opreserved cells, as well the progressive loss of transgenic cells
in all cases of ACT, there may be utility in modalities which
provide a continuous supply of transgenic T cells to the
patient. Previous preclinical models have demonstrated that
TCR-transduced CD34+ peripheral blood stem cells can
endogenously differentiate into fully functional T cells
expressing the TCR of interest.43–45 Such models may yield
improved clinical outcomes by circumventing many of
the short and long-term phenotypic disadvantages of
current ACT manufacturing practices which have been
demonstrated.
Our study has several limitations. The relatively low
number of patients per cohort, combined with the possible
statistical effect of multiple parameter testing, limited our
ability to calculate signiﬁcant population statistics for
comparison. Analysis of larger data sets, as well as utilizing
more rigorously controlled in vitro and in vivo models for
longer periods, may yield additional phenotypic and func-
tional variations between different manufacturing and
administration protocols. In addition, we were only able to
obtain biopsies to examine postinfusion TILs in 2 patients,
and these represented only a small fraction of live lympho-
cytes (∼1400 for patient F5-1, and ∼130 for patient F5-2),
likely due to the variability of T-cell inﬁltration between
individual tumors. However, the relatively high proportion
of transgenic T cells present within the tumors, combined
with the differences when compared with the negative con-
trol tetramer, support the inference that transgenic T cells
were able to track to the tumors analyzed. Furthermore,
limitations in the surface marker panels utilized prevented
us from describing the changes in individual surface markers
over time stratiﬁed by different transgenic T-cell pheno-
types, as well as characterizing additional subsets of T cells,
such as stem cell memory T cells (TSCM), which are also of
great importance in maintaining successful ACT immuno-
therapy. The use of newer technologies, such as mass
cytometry by time-of-ﬂight, which merges single-cell ﬂow
cytometry with mass spectrometry, enables the monitoring
of many more simultaneous factors than conventional ﬂow
cytometry.46,47 Use of this technology will allow for more
sophisticated monitoring of many more T-cell phenotypes in
our future ACT studies.
In conclusion, our study demonstrates that shorter
ex vivo expansion times of transgenic T cells for ACT are
associated with increased markers of naive and memory
populations of T cells, as well as decreased PD1 expression.
Furthermore, fresh cell product infusions were associated
with persistence/expansion of memory compartments of
transgenic T cells, as well as delayed acquisition of PD1
expression. These dual characteristics may explain our pre-
vious experiences in which patients receiving fresh cell
products displayed superior persistence of transgenic T cells,
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as well as superior augmentation of this persistence in
response to DC vaccination. These results may be useful in
design and optimization of future ACT manufacturing pro-
tocols, as well as augmenting their effectiveness via addition
of immunomodulatory agents blocking inhibitory receptors.
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